Recordati to license Gedeon Richter's antipsychotic cariprazine in western Europe

2 August 2016

Italian drugmaker Recordati (RECI: MI) and Hungary’s Gedeon Richter (RICHT: HB) have announced the signing of an exclusive license agreement to commercialize cariprazine, a new antipsychotic drug, in western Europe, Algeria, Tunisia and Turkey.

Cariprazine was discovered by Gedeon Richter scientists and is licensed to Ireland-incorporated Allergan (NYSE: AGN) in Canada and the USA, with the product receiving approval from the US Food and Drug Administration (FDA) in September 2015.

It was launched in the USA in March this year under the trade mark of Vraylar for the treatment of bipolar mania and schizophrenia. The European Medicines Agency (EMA) also started the evaluation of Gedeon Richter’s marketing authorization application for cariprazine for the treatment of schizophrenia in March this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK